本文關(guān)鍵詞： 抗艾滋病毒藥物 銷售金額 用藥頻度 日均費用 職業(yè)暴露　出處：《中國藥房》2017年17期 　論文類型：期刊論文

【摘要】：目的:為臨床合理使用及管理抗艾滋病毒藥物提供參考,并為職業(yè)暴露制訂免費用藥政策提供依據(jù)。方法:采用回顧性研究方法,按照世界衛(wèi)生組織推薦的限定日劑量(DDD)法進行計算,對我中心2011-2014年使用抗艾滋病毒藥物的銷售金額、用藥頻度(DDDs)、日均費用(DDC)和序號比(B/A)等進行分析和評價。結(jié)果:我中心2011-2014年抗艾滋病毒藥物銷售金額呈先升高后降低的趨勢,由2011年的512 112元上升至2012年的650 854元,然后逐年降低至2014年的496 473元;DDDs由2011年的35 932逐年下降至2014年的16 363。核苷酸類逆轉(zhuǎn)錄酶抑制劑的銷售金額在2012-2014均列第1位,DDDs在2011、2013、2014年均列第1位。齊多夫定片的DDDs在2013、2014年列第1位,唐草片的DDDs在2011-2014年均列前3位。富馬酸替諾福韋二吡呋酯片、齊多拉米雙夫定片、恩曲他濱替諾福韋片、洛匹那韋利托那韋片的DDC較高,在46元以上;齊多夫定片、司他夫定片、奈韋拉平片的DDC較低,在6元以下。富馬酸替諾福韋二吡呋酯片、司他夫定片和依非韋倫片的B/A值4年均在0.5~1.5,唐草片在2013、2014年的B/A=1,社會效益和經(jīng)濟效益同步性較好。結(jié)論:我中心抗艾滋病毒藥物臨床使用基本合理,藥物應(yīng)用與職業(yè)暴露預(yù)防用藥基本相符,中藥制劑的應(yīng)用符合臨床用藥需求。
[Abstract]:Objective: to provide a reference for the rational use and management of anti-HIV drugs in clinic and to provide the basis for the establishment of free drug use policy for occupational exposure. In accordance with the limited daily dose DDD method recommended by the World Health Organization, the amount of sales of anti-HIV drugs used by our center in 2011-2014 was calculated. The frequency of drug use was analyzed and evaluated by DDDsN, daily average cost (DDC) and serial number (B / A). Results: the sales amount of anti-HIV drugs in our center increased first and then decreased from 512,112 yuan on 2011 to 650,854 yuan on 2012, the results showed that the sales amount of anti-HIV drugs in our center increased first and then decreased from 512,112 yuan on 2011 to 650,854 yuan on 2012. In 2014, the DDDs decreased from 35932 on 2011 to 16363.The sales amount of nucleotide reverse transcriptase inhibitors ranked first in 2012-2014 in 2011 / 2011, and in 2014 in 1st place. DDDs of zidovudine tablets was ranked first. In 2013, in 2014, No. 1, The DDDs of Tangcao tablets was in the top 3 in 2011-2014. The DDC of tenofovir Fumarate dipyrifuroxime tablets, zidolamitine difurofovir tablets, entrotropine tenofovir tablets and Lopinowilitonavir tablets were higher than 46 yuan. The DDC of stavudine tablets was lower than that of nevirapine tablets, which was below $6. Tenofovir dipyrifuroxime fumarate tablets, The average value of B / A of Stavudine tablets and Efeveron tablets was 0.5 ~ 1.5 a year, and B / A of Tangcao tablets in 2003 and 2014 was better. Conclusion: the clinical use of anti-HIV drugs in our center is basically reasonable. The drug use is basically consistent with the occupational exposure prevention medication, and the application of traditional Chinese medicine is in line with the clinical needs.
【作者單位】： 重慶市公共衛(wèi)生醫(yī)療救治中心藥劑科;
【分類號】：R978.7

【相似文獻】

相關(guān)期刊論文 前4條

1 ;Polγ酶結(jié)構(gòu)的發(fā)現(xiàn)為研制毒性較低的抗艾滋病毒藥物指明方向[J];廣東藥學(xué)院學(xué)報;2009年05期

2 吳焱;;歐盟批準(zhǔn)第二種“三合一”抗艾滋病毒藥物復(fù)合片劑Eviplera[J];上海醫(yī)藥;2012年05期

3 馬培奇;;美FDA批準(zhǔn)第二種“三合一”抗艾滋病毒藥物制劑Complera[J];上海醫(yī)藥;2011年11期

4 ;[J];;年期

，

本文編號：1527787